---
$id: https://graph.org.ai/products/commodity/51111856
$type: Product
source: UNSPSC
code: "51111856"
title: "Lapatinib"
class: "51111800"
classTitle: "Hormones and antihormones"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Lapatinib

**UNSPSC Code**: 51111856
**Class**: [Hormones and antihormones](Hormones and antihormones.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C29H26CLFN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VUA21238F. European Medicines Agency schedules lapatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25379. The term LAPATINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 1, 2004, list 51). Most nations schedule lapatinib under HS 29349990 and SITC 51579. As of Q4 2014, LAPATINIB remains the US FDA Preferred Term for this commodity. Lapatinib bears US NLM identifiers UMLS ID C1506770 and NCI Concept Code C26653. SMILES: CLC1CC(NC2NCNC3C2CC(C2OC(CNCCS(=O)(=O)C)CC2)CC3)CCC1OCC1CC(F)CCC1.

